The cervical cancer screening and management guidelines outlined below are recommended by professional societies in the United States. Other countries are adopting and implementing guidelines according to their own developed policies and recommendations.
July 30, 2020 American Cancer Society Guidelines Update
Recommendations include an HPV test every five years for individuals with a cervix ages 25-65 as the preferred method of testing over the Pap test or the combination of Pap and HPV testing. Another significant change is for cervical cancer screening to begin at age 25. The previous ACS guideline, released in 2012, called for cervicl cancer screening starting at age 21.
The new guidelines reflect the rapidly changing landscape of cervical cancer prevention in the United States and around the world, focusing on better outcomes, test efficiency and more simplified screening. Human papillomavirus (HPV) is the cause of nearly all cervical cancers. Primary HPV testing every 5 years is more effective than Pap cytology alone for cervical cancer prevention, and more efficient than co-testing, reducing the number of tests while providing comparable outcomes.1, 2
April 2, 2020—The ASCCP Risk Based Management Consensus Guidelines have now been published. Read here: https://journals.lww.com/jlgtd/pages/currenttoc.aspx?sessionEnd=true
ASCO Secondary Prevention of Cervical Cancer Resource-Stratified Guideline: https://www.asco.org/research-guidelines/quality-guidelines/guidelines/gynecologic-cancer#/14021 published in JGO DOI: 10.1200/JGO.2016.006577
US Preventive Services Task Force (USPSTF) Guidelines update August 21, 2018: https://www.uspreventiveservicestaskforce.org
American College of Obstetrics & Gynecology Practice Advisory update August 2018: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2018/08/cervical-cancer-screening-update
Society of Gynecologic Oncology (SGO): https://www.sgo.org/clinical-practice/guidelines/
American Cancer Society (ACS): https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/cervical-cancer-screening-guidelines.html
cobas® HPV tests run on cobas® Systems, based on Nobel prize-winning PCR technology. cobas® Systems enable consolidated assay menu, backed by extensive experience and expertise in test design and optimization. cobas® Systems deliver full automation, increased throughput and faster turnaround time, providing users with greater flexibility to increase overall workflow efficiencies. The broad menu includes assays for viral load monitoring, donor screening, women’s health and microbiology/other STI screening.
Our commitment to robust standards demonstrates an unparalleled dedication to thorough data analysis and validation, so that you can have the utmost confidence in every result. Click here to learn more about our continued investment in new assay solutions and expanded menu offering.
With today's scientific advancements and our current understanding of the science behind HPV, we no longer believe that the status quo in cervical screening is good enough. Roche continues to make significant investment in screening strategies, product development, and clinical study evidence, because we know that you expect this and that women deserve more.
The Roche cervical cancer portfolio is unique in that it supports women along a continuum of care, enabling physicians to screen and diagnose disease, before invasive cancer ever develops. We help laboratories and clinicians by providing additional information about a patient's risk so that her care is more individualized, and there is evidence behind important treatment decisions. Giving a woman the right care at the right time will not only help protect her from the progression of disease, but can also help protect her from the risk or over- or under-treatment.
The IMPACT Trial supports the FDA approval of multiple products, including CINtec® PLUS Cytology.
The ATHENA Trial was a large, prospective clinical study evaluating performance of the cobas® HPV test in multiple screening scenarios, including HPV primary screening, ASC-US triage, and co-testing (Pap and HPV tests at the same time).
Many published articles and papers support the advancement of science around HPV and cervical cancer prevention. The science behind HPV and its role in disease progression has opened up new pathways for patient management and care. Please see below for a summary of clinical study publications that have been significant in shaping and supporting today's understanding to guide clinical practice.